ISPOR 15th Annual European Congress Banner
Program: Wednesday, 7 November 2012
7:30-8:30
EDUCATIONAL SYMPOSIUM (Sponsored by IMS Health)
INFORMATION TECHNOLOGY: POWERING THE NEXT GENERATION OF OUTCOMES RESEARCH AND HEALTH CARE DELIVERY
See Symposium Description »

Breakfast available prior to the presentation for symposium attendees
8:45 - 14:45
RESEARCH POSTER PRESENTATIONS VIEWING – SESSION V
8:45 - 9:45
WORKSHOPS – SESSION IV
8:45 - 9:45
W19: PREDICTIVE MODELLING OF REAL-WORLD OUTCOMES: HOW USEFUL FOR HTA EVALUATIONS?
Discussion Leaders:

Billy Amzal, PhD, Senior Scientific Vice President, LA-SER Analytica, London, UK; Venkat Timmaraju, PhD, Senior Statistical Consultant, LA-SER Analytica, London, UK; Helene Karcher, PhD, Expert Modeler, Novartis Pharma AG, Basel, Switzerland; Adam Lowy, MB, ChB, MSc, Expert Global Epidemiologist, Novartis Pharma AG, Basel, Switzerland

8:45 - 9:45
W20: META-ANALYSIS OF RARE EVENTS: SUGGESTING A PRACTICAL GUIDANCE
Discussion Leaders:

Julie Roiz, MSc, Project Leader, HEOR, OptumInsight, Nanterre, France; B. Schweikert, PhD, Senior Lead Analyst, Life Sciences, OptumInsight, Munich, Germany; Keith Abrams, MSc, PhD, Professor of Medical Statistics, Department of Health Sciences, University of Leicester, Leicester, UK

8:45 - 9:45
W21: WHY, WHEN AND HOW TO CONDUCT ECONOMIC EVALUATIONS USING COMPREHENSIVE DECISION ANALYTICAL MODELING?
Discussion Leaders:

Samuel Aballea, MSc, Director, HEOR, Creativ-Ceutical, Paris, France; Benjamin Briquet, BSc, Student, Paris Institute of Statistics (ISUP), Paris, France; Clément François, PhD, Divisional Director, Global Outcomes Research, Lundbeck SAS, Issy-les-Moulineaux, France; Anne-Lise Vataire, MSc, Senior Analyst, Creativ-Ceutical, Paris, France

8:45 - 9:45
W22: USING TIME DEPENDENT ENDPOINTS TO INFORM REIMBURSEMENT DECISION OF CANCER DRUGS IN THE ABSENCE OF MATURE OVERALL SURVIVAL DATA
Discussion Leaders:

Jorge Félix, MSc, Director, Exigo Consultores, Alhos Vedros, Setúbal, Portugal; Anant Murthy, PhD, Executive Director, Global Pricing and Market Access, Celgene Corporation, Boudry, Switzerland; Stefan Michiels, PhD, Biostatistician, Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Brussels, Belgium

8:45 - 9:45
W23: UNIFYING COVERAGE AND RESEARCH DECISIONS: HOW CAN QUANTITATIVE ANALYSIS INFORM THE ASSESSMENTS REQUIRED?
Discussion Leaders:

Karl Claxton, PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK; Adrian Towse, MA, MPhil, Director, Office of Health Economics, London, UK; Claire McKenna, PhD, Research Fellow, Centre for Health Economics, University of York, Heslington, York, UK; Marta O Soares, MSc, Research Fellow, University of York, Heslington, York, UK

9:45 - 10:00
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION V
10:00 - 11:00
ISSUE PANELS – SESSION III
10:00 - 11:00
IP11: CAN VALUE OF INFORMATION ANALYSIS BE USED ROUTINELY TO INFORM RESEARCH PRIORITIZATION DECISIONS?
Moderator: Mark J. Sculpher, MSc, PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
Panelists:

Karl Claxton, PhD, Professor of Economics, Centre for Health Economics, University of York, Heslington, York, UK; Lotte MG Steuten, PhD, Associate Professor, Department of Health Technology and Services Research, University of Twente and Director, Health Economics and Reimbursement, PANAXEA b.v., Twente, The Netherlands; Rachael Fleurence, PhD, Director, Patient-Centered Outcomes Research Insitute (PCORI), Washington, DC, USA

10:00 - 11:00
IP12: REFLECTING METHODOLOGICAL AND ENVIRONMENTAL CHANGE IN HTA METHODS: IS THE 2012 NICE GUIDE TO THE METHODS FOR TECHNOLOGY APPRAISAL THE ANSWER?
Moderator: Paul Tappenden, MSc, Senior Research Fellow, HEDS, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
Panelists:

Andreas Gerber, PhD, MD, Head, Health Economics, Institute of Quality and Efficiency in Health Care (IQWiG), Cologne, Germany; Elisabeth George, PhD, Associate Director, Centre for Health Technology Evaluation, National Institute for Health and Clinical Excellence, Manchester, UK; Stephen Palmer, MSc, Professor, Centre for Health Economics, University of York, York, North Yorkshire, UK

10:00 - 11:00
IP13: PERSONALIZED MEDICINE FROM A HEALTH SYSTEMS PERSPECTIVE: HOW CAN WE BETTER LEVERAGE EVIDENCE TO ADDRESS MULTIPLE STAKEHOLDER NEEDS?
Moderator: Eric Faulkner, MPH, Director, Global Market Access, Consulting, Quintiles Global Consulting, Durham, NC, USA
Panelists: Diego F. Ossa, MD, MSc, Global Head, HEOR MDx, Novartis Pharma AG, Basel, Switzerland; Ansgar Hebborn, PhD, Head, Global Payer & HTA Program Policy, F. Hoffmann-La Roche AG, Basel, Switzerland; Uwe Siebert, MD, MPH, MSc, ScD, Professor, Department of Public Health and Health Technology Assessment, UMIT/Oncotyrol/Harvard University, Hall i.T., Austria
10:00 - 11:00
IP14: WILL THE EUNETHTA MODEL FOR RAPID RELATIVE EFFECTIVENESS ASSESSMENT (REA) OF PHARMACEUTICALS WORK?
Moderator: Wim Goettsch, PhD, Project Leader of EUnetHTA WP5 on Relative Effectiveness of Pharmaceuticals and Health Care Insurance Board (CVZ), Diemen, The Netherlands
Panelists: Mel Walker, MRPharmS, PhD, FRS, Senior Director, GlaxoSmithKline, Brentford, Middlesex, UK; Marianne Klemp, PhD, Director, The Norwegian Knowledge Centre for the Health Services (NOKC), Oslo, Norway; Mirjana Huic, MD, MsC, Assistant Director, Agency for Quality and Accreditation in Health Care and Social Welfare, Zagreb, Croatia
10:00 - 11:00
IP15: CAN THERE BE A COMMON METHODOLOGY FOR COMPARATIVE EFFECTIVENESS IN THE ABSENCE OF RANDOMISED CONTROLLED TRIALS (RCTS)?
Moderator: Pascale Brasseur, MSc, Reimbursement Director, Cardiovascular Reimbursement and Health Economics, Medtronic International Trading Sàrl, Tolochenaz, Switzerland
Panelists: Isabelle Durand-Zaleski, PhD, Professor of Medicine, Head of Public Health, Director of the CRU ECO Ile-De-France, Créteil, France; Rod Taylor, MSc, PhD, Professor in Health Services Research, Peninsula Medical School, Exeter, UK; David A Scott, MSc, MA, Senior Director, Health Economics, Oxford Outcomes, Oxford, UK
11:15 - 12:30
WELCOME & THIRD PLENARY SESSION
WELCOME
Deborah Marshall, PhD, MHSA

Deborah Marshall, PhD, MHSA
2012-2013 ISPOR President and Associate Professor, University of Calgary and University of McMaster, Director, HTA, Alberta Bone and Joint Health Institute & Canada Research Chair, Health Services and Systems Research Centers, Calgary, AB, Canada

 
It is assumed that people make, or should make, rational choices based on self-interest.  For conventional health economic evaluations, self-interest is approximated by individual preferences, such as maximum willingness-to-pay (WTP) in the case of cost-benefit analysis or quality-adjusted life years (QALY) in the case of cost-utility analysis. Efficiency is achieved when aggregate benefits (WTP or QALYs) are maximized under a resource constraint.  However, there is now overwhelming evidence that people exhibit a ‘regard for others’ or “social” preferences, which systematically differ from the “efficiency” objective underlying the WTP or QALY maximization hypothesis.  Well-documented social preferences include inequity aversion, concerns for fairness, reciprocity and altruism, but also spiteful or envious preferences.  This raises important issues. If health economic evaluations are intended to aid health policy makers in resource allocation decisions, what do we really know about social preferences for health care resource allocation?  What are the nature of social preferences, and how can they be measured appropriately?  How can social preferences be incorporated in formal health technology assessments and allocation of scarce health care resources?
Michael Schlander, MD, PhD, MBA Moderator:
Michael Schlander, MD, PhD, MBA
Professor, Health Care and Innovation Management, University of Heidelberg and Chairman & Scientific Director, Institute for Innovation & Valuation in Health Care (InnoVal), Wiesbaden, Germany
Erik Nord, PhD Speakers:
Erik Nord, PhD
Senior Researcher, Norwegian Institute of Public Health, Oslo, Norway
Jeff Richardson Jeff Richardson, PhD
Professor, Department of Business and Economics and Foundation Director of the Centre for Health Economics, Monash University, Melbourne, Australia
Christian Affolter, PhD, MBA
Head of Foundations, santésuisse, Solothurn, Switzerland
12:30 - 12:45
ISPOR 15th ANNUAL EUROPEAN CONGRESS RESEARCH PRESENTATION AWARDS
 

Moderator: Deborah Marshall, PhD, MHSA, 2012-2013 ISPOR President and Associate Professor, University of Calgary and University of McMaster, Director, HTA, Alberta Bone and Joint Health Institute & Canada Research Chair, Health Services and Systems Research Centers, Calgary, AB, Canada

ISPOR BEST PODIUM PRESENTATIONS
Presented by: Axel Mühlbacher, PhD, Professor, Health Economics and Health Care Management, Hochschule Neubrandenburg, Neubrandenburg, Germany

ISPOR BEST POSTER PRESENTATIONS
Presented by: Luciana Scalone, PhD, PharmD, ScD, Researcher, Research Centre on Public Health, University of Milan-Bicocca, Monza, Italy

12:45 - 13:45
LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION V
12:45 - 13:45
POSTER AUTHOR DISCUSSION HOUR – SESSION V
13:45 - 14:45
WORKSHOPS – SESSION V
13:45 - 14:45
W24: SURVIVAL ANALYSIS IN HTA: IS CURRENT PRACTICE BEST PRACTICE?
Discussion Leaders:

John William Stevens, PhD, Statistician, School of Health & Related Research (ScHARR), University of Sheffield, Sheffield, UK; Noemi Muszbek, MSc, Research Scientist, United BioSource Corporation, Budapest, Hungary; Martin William Hoyle, MA, PhD, Senior Research Fellow, PenTAG, University of Exeter, Exeter, UK; Edit Remak, MSc, Research Scientist, United BioSource Corporation, Budapest, Hungary

13:45 - 14:45
W25: ISSUES IN MODELING THE PROGNOSIS AND TREATMENT OF NON-COMMUNICABLE DISEASES USING PATIENT-LEVEL SIMULATION: DO THE GUIDELINES HELP US?
Discussion Leaders:

Talitha L. Feenstra, PhD, Health Economist, Epidemiology, University Medical Centre Groningen and RIVM, Groningen, The Netherlands; Christian Asseburg, PhD, MSci, Technical Director, ESiOR Oy, Kuopio, Finland; Annemieke Leunis, MSci, Researcher, Institute for Medical Techonology Assessment (iMTA), Rotterdam, The Netherlands; Paul F. M. Krabbe, PhD, Associate Professor, Department of Epidemiology, University of Groningen, Groningen, The Netherlands

13:45 - 14:45
W26: HETEROGENEITY IN COST EFFECTIVENESS ANALYSIS: IMPLEMENTING METHODS TO REALISE ITS VALUE
Discussion Leaders:

Pedro Saramago, MSc, Research Fellow, Centre for Health Economics, University of York, York, Heslington, UK; Manuel Antonio Espinoza, MD, MSc, PhD Student, Centre for Health Economics, University of York, Heslington, York, UK; J. Grutters, PhD, Postdoctoral Researcher, School for Public Health and Primary Care, Maastricht University, Maastricht, Limburg, The Netherlands; JL (Hans) Severens, PhD, Professor of Evaluation in Health Care, Institute of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands

13:45 - 14:45
W27: ASSESSING THE REIMBURSABILITY OF NEW PRODUCTS: A STRUCTURED APPROACH
Discussion Leaders:

Joseph DiCesare, MPH, Global Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Lou Garrison, PhD, Professor, University of Washington School of Pharmacy, Seattle, WA, USA; Gerry Oster, PhD, Vice President, Policy Analysis Inc. (PAI), Brookline, MA, USA; Patricia Sacco, MPH, RPh, Director, HEOR, Novartis Pharmaceuticals Corporation, Hanover, NJ, USA

13:45 - 14:45
W28: THE TRADE-OFF BETWEEN QUALITY AND COSTS OF PRIMARY HEALTH CARE: THEIR IMPACT IN THE PROCESS OF DECISION-MAKING
Discussion Leaders:

Antonio Sarría, MD, MPH, Director, Health Technology Assessment Agency, Instituto de Salud Carlos III, Madrid, Spain; Simo Kokko, MD, PhD, Senior Professor & Researcher, National Institute for Health and Welfare, Helsinki, Finland; Marje Oona, MD, PhD, Assistant Professor, Senior Researcher, Department of Family Medicine, University of Tartu, Tartu, Estonia; Kadri Suija, MD, PhD, Researcher, Department of Family Medicine, University of Tartu, Tartu, Estonia

14:45 - 15:00
BREAK & EXHIBITS VIEWING
15:00 - 16:00
WORKSHOPS – SESSION VI
15:00 - 16:00
W29: SAMPLE SIZE ESTIMATION FOR OBSERVATIONAL STUDIES
Discussion Leaders:

Terry Alan Cox, MD, PhD, Director, Biostatistics, Real World & Late Phase Research, Quintiles Outcome, Rockville, MD, USA; Eric Gemmen, MA, Senior Director, Biostatistics & Outcomes Research, Real World & Late Phase Research, Quintiles Outcome, Rockville, MD, USA; Mark Nixon, PhD, Director, Biostatistics, Real World & Late Phase Research, Quintiles Outcome, Reading, Berkshire, UK; Pablo Mallaina, MD, MPH, PhD, Senior Medical Manager - Champix, Primary Care BU Europe Canada Australia & NZ (PECANZ), Pfizer, Inc., Madrid, Spain

15:00 - 16:00
W30: DEMONSTRATING THE BENEFITS OF ONCOLOGY TREATMENTS: MINIMISING UNCERTAINTY AND BIAS
Discussion Leaders:

Nicholas Latimer, MSc, Research Fellow in Health Economics, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, South Yorkshire, UK; Neil Hawkins, PhD, Vice President, Health Economics, Oxford Outcomes, Oxford, UK; Mike Spencer, MSc, Senior Director, Health Economics, Market Access and Reimbursement, Janssen EMEA, Janssen-Cilag Limited, High Wycombe, Bucks, UK

15:00 - 16:00
W31: FROM DECISION POINT TO DECISION WINDOW: READINESS FOR A CHANGE OF PARADIGM
Discussion Leaders:

Mondher Toumi, MD, PhD, Professor, Market Access, University Claude Bernard Lyon 1, Lyon, France; Thomas Mueller, MD, Head, Pharmaceuticals Department, Federal Joint Committee (G-BA), Berlin, Germany

15:00 - 16:00
W32: LISTENING TO THE PATIENT- DEVELOPING STRATEGIES FOR ENHANCING THE USE OF DATA RELEVANT TO PATIENTS IN HEALTHCARE DECISION MAKING
Discussion Leaders:

Michelle Mocarski, MPH, Manager, Health Economics and Outcomes Research, Forest Research Institute, Inc., Jersey City, NJ, USA; Asha Hareendran, PhD, MA, Senior Research Scientist, United BioSource Corporation, London, UK; Keith Tolley, Mphil, BA, Director, Tolley Health Economics, Buxton, UK

15:00 - 16:00
W33: INCREASED STATISTICAL POWER FOR PRO OUTCOMES – USING ITEM RESPONSE THEORY METHODS TO DEVELOP COMPOSITE SCALES
Discussion Leaders:

Jakob Bue Bjorner, PhD, Chief Science Officer, QualityMetric, OptumInsight Life Sciences, Lincoln, RI, USA; Mark Kosinski, MA, Senior Scientist & Vice President, Outcomes Insight Consulting, QualityMetric, OptumInsight Life Sciences, Lincoln, RI, USA; Matthias Rose, MD, PhD, Professor, Department of Psychosomatic Medicine, Charité - University of Medicine, Berlin, Germany